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Abstract
Background: The stability limit of an analyte in a biologi­
cal sample can be defined as the time required until a 
measured property acquires a bias higher than a defined 
specification. Many studies assessing stability and pre­
senting recommendations of stability limits are available, 
but differences among them are frequent. The aim of this 
study was to classify and to grade a set of bibliographic 
studies on the stability of five common blood measur­
ands and subsequently generate a consensus stability 
function.
Methods: First, a bibliographic search was made for sta­
bility studies for five analytes in blood: alanine amino­
transferase (ALT), glucose, phosphorus, potassium and 
prostate specific antigen (PSA). The quality of every study 
was evaluated using an in­house grading tool. Second, the 
different conditions of stability were uniformly defined 
and the percent deviation (PD%) over time for each analyte 
and condition were scattered while unifying studies with 
similar conditions.
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Results: From the 37 articles considered as valid, up to 
130 experiments were evaluated and 629 PD% data were 
included (106 for ALT, 180 for glucose, 113 for phospho­
rus, 145 for potassium and 85 for PSA). Consensus stability 
equations were established for glucose, potassium, phos­
phorus and PSA, but not for ALT.
Conclusions: Time is the main variable affecting stability 
in medical laboratory samples. Bibliographic studies dif­
fer in recommedations of stability limits mainly because 
of different specifications for maximum allowable error. 
Definition of a consensus stability function in specific 
conditions can help laboratories define stability limits 
using their own quality specifications.
Keywords: blood specimen collection; pre­analytical 
phase; specimen handing; stability.
Introduction
Stability is the capability of a sample material to retain 
the initial property of a measurand for a period of time 
within specified limits when the sample is stored under 
defined conditions [1]. The stability is mainly affected by 
storage time and also by other factors that increase the 
metabolism of the analyte or cause the initial property to 
disappear, such as temperature, light exposure, solvent 
evaporation or stirring.
The change in the property over time can be expressed 
as percent deviation (PD%) or bias with respect to the 
initial value, whereas the deterioration can be defined as 
a function that represents the variation of PD% over time. 
It can also be graphically represented in a two­dimen­
sional chart with the PD% in the y­axis and the time in the 
x­axis, similar to the habitual representation of the dose­
response in relation to an interfering substance. In fact, 
both interferences and instability in a particular sample 
are the main components of specimen­specific sistematic 
error. The stability limit for an analyte is defined as the 
point in time when the PD% reaches a given specification 
of maximum allowable error. Similar to dose­response 
graphs for interferences, stability limits may also be easily 
extrapolated from such graphs.
It should be noted that this equation is modified by 
the physical­chemical factors that facilitate the process 
of instability, mainly contact with air, temperature, light 
exposure or agitation. This means that the stability limit 
needs to be defined for specific conditions (e.g. blood 
glucose stability in whole blood in closed tube, at room 
temperature, protected from light and without stirring).
Although a myriad of experimental studies assess­
ing the stability of most laboratory magnitudes in various 
conditions may be found in the literature, there are few 
clinical guidelines with general recommendations for the 
laboratory. The most widely used is the recommendation of 
the German Society of Clinical Chemistry (DGKL), published 
in a WHO report and later updated [1]. These recommen­
dations are based on the collection of published studies, 
and separated into two basic conditions of stability; the 
specimen, as obtained from the patient, and the sample, 
prepared for analysis. The controversy within this recom­
mendation is that stability limits of the reviewed studies 
are directly assumed or arbitrarily summarized. Noticeable 
aspects affecting this situation are the variability in the 
methodology and the quality of the studies included (some 
of them were performed a long time ago, using materials 
that are nowadays obsolete) and the different criteria to 
define the degree of deterioration that hamper the estab­
lishment of a rejection recommendation (maximum allow­
able error), even though the document includes a specific 
recommendation for the MAE based on biological variation 
(half of the total allowable error), included studies use dif­
ferent criteria, sometimes purely metrological or statistical. 
This may be due to the absence of clinical guidelines for the 
design of stability studies in clinical samples, in contrast 
with other components of total error, such as imprecision, 
accuracy or interferences. Therefore, the studies pub­
lished follow different procedures, have variable number 
of samples, different statistical approaches and different 
maximum allowable error criteria.
The aim of this study was to classify and to grade a set 
of bibliographic studies about the stability of five common 
blood measurands and subsequently generate a consen­
sus stability function. For this pilot study we selected five 
magnitudes, four of them with well­known stability prob­
lems (glucose, potassium, phosphorus and specific pros­
tate antigen) and one of them usually mentioned as stable 
(ALT). These models could help medical laboratories to 
define stability limits based on their own specifications 
of maximum allowable error for the pre­analytical phase.
Materials and methods
Scientific bibliographic search
The analytes selected for the validation of this method 
were alanine aminotransferase (ALT), glucose, potas­
sium, phosphorus and prostate­specific antigen (PSA).
The search strategy in PUBMED included: “(sample 
OR samples OR specimen OR specimens) AND (stability 
OR deterioration OR preanalytical OR pre­analytical)” in 
the last 15  years. A total of 1084 entries were obtained. 
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The acceptable articles were selected by two members of 
the Committee by checking the abstracts. Acceptability 
included inclusion of ALT, glucose, potassium, phospho­
rus or PSA in blood in the study. Forty­eight references 
were finally included [2–50].
Acceptability of bibliographical references
In order to grade the quality of the papers, a checklist was 
defined including all variables that could affect the stabil­
ity of selected magnitudes in blood (Table 1). Every item 
was rated as 0 if not considered for the study design, 1 if 
included and 2 if it improved the design. The maximum 
score was 29 points. References were classified into four 
grades: excellent if the score was above 21.75 points, 
acceptable if it was between 14.5 and 21.75 points, doubt­
ful if between 7.25 and 14.5 points and unacceptable if the 
score was lower than 7.25 points. Scoring and grading of 
every reference was performed by the members of the 
Committee, in pairs. In case of discrepancies in grading, 
a new revision by another member was performed and an 
average score was obtained.
Stability conditions
In order to compare the primary data of PD%, it is essential 
that the different studies have similar experimental condi­
tions. Hence, a second checklist was prepared to compile 
the performance conditions of each stability experiment 
included.
The items included in this checklist were:
1. Strict definition of the system: the sample type (whole 
blood, serum or plasma) and the container/addi­
tive used (including manufacturer reference when 
available).
2. Procedure for blood collection.
3. Temperature of collection and storage.
4. Light exposure.
5. Stirring.
6. Evaporation (i.e. open tube during study).
7. Sample storage until the analysis.
8. Laboratory instrumentation.
9. Analytical methodology.
10. Batch analysis. (i.e. whether analyses were made in 
one single batch or multiple series).
Stability models and statistical analysis
PD% for each magnitude and stability condition was 
modeled by linear or curvilinear regression using the least 
squares adjustment over time. The regression equation 
was forced to include the point (0.0) (the model does not 
include any constant) as by definition, PD% was zero at 
the beginning of the experiment. The adjustment equa­
tion (linear, polynomic or exponential) was selected by 
improvement of R2. The strength of the fit was assessed by 
the Pearson’s coefficient of correlation, considering r >0.7 
as a good adjustment, and its significance by Snedecor’s 
F­test (ANOVA). Statistical significance was set at 0.01. IBM 
SPSS v21 software was used for all statistical analyses.
Results
Forty­eight bibliographical references were selected, 11 
of which were discarded as not presenting valid primary 
data to calculate PD%. In the 37 valid references, up to 130 
different experiments were included; 48 in whole blood, 
30 in plasma and 52 in serum. Of the five magnitudes 
assessed, 629 valid stability PD% data were collected: 180 
for glucose, 113 for phosphorus, 145 for potassium, 106 for 
ALT and 85 for PSA (35 for total PSA and 50 for free PSA). 
Forty data points for glucose stability studies used glyco­
lysis inhibitors, and were excluded due to the heterogene­
ity of tube types.
In the 48 peer­reviewed references, the average score 
was 18.3 points (SD 3.83, range 8.0–24.5), and were graded 
as: three unacceptable, seven doubtful, 28 acceptable and 
10 excellent. Only in two cases there was a discrepancy 
between reviewers, and a third revision was included. The 
items included in the evaluation checklist are outlined 
in Table 1, as well as the percentage of studies found for 
every condition.
Most studies used healthy subjects (60.4%) instead of 
patient samples. The typical sample size was between 10 
and 30 individuals (45.8%), often with a single determi­
nation (68%). The procedure of blood collection was fre­
quently defined (73%) and often appropriate in terms of 
duration and volume (62.9%). The venipuncture devices 
were usually commercial and vacuum systems were used 
(90.5%) which could warrant a controlled contact with air 
during the experiment. However, in 52% of the references 
this aspect was not clearly reflected.
Temperature was controlled throughout the process 
in 87.5% of the references, but not agitation (31%), nor 
light exposure (27%). Centrifugation conditions, includ­
ing force and time and sample storage until centrifugation 
were properly defined in 60.5% and 82.1% of the refer­
ences, respectively.
Once the stability experiment finished, samples were 
analyzed immediately or deep­frozen to be processed in 
batch (95.3%). The analytical methods were correctly 
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defined in 85% of the references, although the quality 
assurance of the process was not mentioned in one third 
of cases (31.8%). The confidence interval for PD% was 
lacking in 30.5% of the articles. Moreover, 27% of the 
studies did not perform any analysis of the differences.
Maximum allowable difference specifications were 
based on biological variation in 17 studies, on metrological 
criteria in 12 studies and exclusively statistical in 13 studies.
Twelve studies did not include any kind of data 
regarding PD% for their magnitudes, neither graphs that 
Table 1: Quality Grading tool.
Item Options Score (points) % Studies
Sample origin – Healthy subjets 1 60.4
– Patients 2 39.6
Sample size, n – <10 0 6.25
– 10–30 1 45.8
– >30 2 47.9
Is the blood collection procedure defined? – No 0 27
– Yes 1 73
Total drawn volumen (mL) and phlebotomy time – Defined and appropriate (<60 mL, <1 min) 2 62.9
– Defined, inappropriate (>60 mL, >1 min) 1 14.5
– Not defined 0 22.6
Are the pre-analytical conditions controlled? – Yes (fasting, rest, time of collection) 1 60
– No 0 40
Is the blood collection tube defined? – Commercial vacuum tube 2 90.5
– Tube without vacuum 1 1
– Not defined 0 8.5
Is the temperature controlled during the experiment? – Yes 1 87
– Not defined 0 13
Is stirring controlled? – Yes 1 31
– Not defined 0 69
Is light exposure controlled? – Yes 1 27
– Not defined 0 73
Is evaporation controlled? – Yes 1 48
– Not defined 0 52
Repose before centrifuging (serum), min – Serum <60, plasma <30 2 82.1
– Serum >60, plasma >30 1 14
– Not defined 0 3.9
Type of centrifugation – Recommended 2 60.5
– Different of recommended 1 17
– Not defined 0 22.5
Sample storage between end of experiment and analysis – Analyzed immediately or deep frozen until analysis 2 87.4
– Inappropriate storage until analysis 1 7.9
– Not defined 0 4.7
Analyzer – Defined 1 88
– Not defined 0 12
Method – Commercial 1 85
– Not defined 0 15
Metrological quality – Defined, appropriate 2 62
– Defined 1 6.2
– Not defined 0 31.8
Repetition of analysis – >Duplicate 2 5.5
– Duplicate 1 26.5
– Simple 0 68
Is confidence interval of the difference calculated? – Yes, in each case 2 63.2
– Yes, only in some cases 1 6.3
– Not defined 0 30.5
Signification of differences – Defined 1 73
Statistical hypothesis testing – Not defined 0 27
Description of the variables that affect the stability and scores for each, together with the percentage of studies for every item.
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allowed an estimate, therefore they were excluded from 
stability models [7, 11, 14, 22, 27–29, 41, 44, 46–48].
With regard to stability conditions
1. Strict definition of the system. Thirteen different con­
ditions were defined, including 57  studies in whole 
blood, 51 in serum and 22 in plasma. In the whole 
blood studies, seven different conditions were con­
sidered (without additives 5, EDTA 4, heparin 12, with 
glycolysis inhibitors 16, non­thrombin procoagulant 
and gel 15, non­thrombin procoagulant without gel 
4, and with thrombin procoagulant 1). In the serum 
studies, two conditions were suggested; non­throm­
bin procoagulant (49 studies) or thrombin procoagu­
lant (two studies). In the plasma studies there were 
16  with heparin, two  with glycolysis inhibitors and 
one with EDTA. Due to the great variety of conditions, 
we moved to a basic classification in two types; whole 
blood vs serum/plasma. The great difference between 
these conditions is cell contact, which is complete in 
whole blood, and reduced to the presence of residual 
cells in serum or plasma. Studies using a glycolysis 
inhibitor were separated in the case of glucose.
2. Blood collection procedure. The most frequent design 
was the collection in primary tubes and used directly 
for analysis (74  studies, 57%). In 39  studies, collec­
tion was performed in the primary tube, but an ali­
quot was used to perform the analysis. In seven cases, 
the drawn tubes were mixed to prepare a pool and in 
seven cases all the necessary volume was collected in 
a different device and secondary tubes were prepared 
for the stability study. Blood collection procedure was 
not defined in three cases.
3. Temperature of collection and storage. Regarding the 
collecting temperature, the great majority of stud­
ies (118) were carried out at room temperature. With 
respect to storage, temperature was usually controlled 
in a narrow range, according to its influence on sta­
bility. The most studied temperatures were 4  °C (28 
experiments), 22  °C (32 experiments) and 27  °C (14 
experiments), although many studies used other tem­
peratures. A basic classification was set as refrigerated 
(range 4–9 °C) or room temperature (RT) (15–27 °C).
4. Light exposure. As already mentioned as a quality 
parameter, only 22 experiments specified protection 
from light during the period assessed.
5. Stirring. It was only controlled in 16 studies.
6. Evaporation. In four studies, the effect of evaporation 
was studied (open tube), in 58 studies the tubes were 
kept capped to avoid evaporation and in 68 studies it 
was not specified.
7. Batch analysis. One hundred and one studies were 
analyzed in several batches and 29 in a single batch. 
Studies made in a single batch are less prone to impre­
cision, but need an extra storage time that could bias 
the results.
8. Sample storage until analysis. In 29 single batch stud­
ies, samples needed to be stored until batch analysis, 
usually frozen or deepfrozen storage [16], however, 
14 were refrigerated.
9. Laboratory instrumentation/Analytical methodology. 
More than 50 different instruments and a great variety 
of methods were registered.
Stability models in basic conditions
With the PD% data collected from the studies, a scatter­
gram of PD% over time expressed in hours was prepared. 
A regression was made using least squares and the sig­
nificance and strength of the adjustment were verified. 
We evaluated the points obtained under similar stabil­
ity conditions for each magnitude. Initially, only sample 
type (whole blood versus serum/plasma) and the most 
common temperatures (room and refrigerated) were 
considered. Table 2 shows the number of references and 
points included, the goodness of fit (Pearson’s r for each 
model), the statistical significance (p­value) and the 
selected equation.
Glucose stability depends mainly on cell contact. 
The uptake and metabolism depend on the activity of the 
glycolytic enzymes, which explains why refrigeration is 
commonly used as a preservation method [51]. In whole 
blood, there is a decrease of approximately 1%/h at room 
temperature and 0.3%/h in whole refrigerated blood. In 
both cases, the equation that best adjusts is a quadratic 
model although the linear model could also be consid­
ered as acceptable (Figure 1). There is a clear increase 
in the rate of degradation with temperature that can be 
verified including the quantitative variable in a multiple 
regression model where both factors are significant (coef­
ficient for time: B = − 0.6%/h, temperature: B = −1.6%/°C). 
Although the average equation obtained shows a slope of 
1%/h, studies at temperatures around 20 °C are close to 
2%/h. Studies of accelerated degradation at 30–37 °C yield 
a decrease approaching 4%/h (Figure 2). Degradation is 
also observed in serum/plasma, with no marked effect on 
temperature. The decrease is around 0.1%/h.
The case of phosphorus is compelling; only a clear 
stability loss in whole blood at room temperature is 
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observed. In refrigerated whole blood, a very slight eleva­
tion was observed (0.2%/h). Serum and plasma produced 
an even lower elevation of 0.07%/h and 0.03%/h at room 
temperature and refrigerated, respectively. In the case of 
whole blood at room temperature, the adjustment by a 
cubic model significantly improved the linear adjustment 
Table 2: Stability models in basic conditions.
Magnitude Stability condition n PD% points Adjust model p-Value r Slope (Standard error)
Glucose Whole blood RT 9 55 Linear <0.001 0.788 –0.944 (0.094)
Quadratic <0.001 0.889 –1743/0.008 (0.135/0.001)
Glucose Whole blood refrigerated 2 15 Linear <0.001 0.820 –0.285 (0.053)
Quadratic <0.001 0.948 –0.699/0.003 (0.083/0.001)
Glucose Serum/plasma RT 7 30 Linear <0.001 0.835 –0.071 (0.010)
Quadratic <0.001 0.875 –0.128/0.000 (0.024/0.0001)
Glucose Serum/plasma refrigerated 6 29 Linear <0.001 0.685 –0.108 (0.022)
Quadratic <0.001 0.773 –0.216/0.001 (0.042/0.0001)
Phosphorus Whole blood RT 10 59 Linear <0.001 0.937 3.776 (0.187)
Quadratic <0.001 0.959 1.826/0.026 (0.394/0.005)
Cubic <0.001 0.975 –1.438/0.135/–0.001 
(0.635/0.019/0.0001)
Phosphorus Whole blood refrigerated 3 12 Linear <0.001 0.877 0.209 (0.035)
Quadratic <0.001 0.992 –0.110/0.002 (0.028/0.0001)
Phosphorus Serum/plasma RT 4 20 Linear <0.001 0.888 0.071 (0.008)
Quadratic <0.001 0.921 0.126/0.000 (0.022/0.0001)
Phosphorus Serum/plasma refrigerated 5 18 Linear <0.001 0.902 0.028 (0.003)
Quadratic <0.001 0.904 0.033/–0.00004 (0.10/0.0001)
Potassium Whole blood RT 12 78 Linear <0.001 0.824 2.366 (0.185)
Quadratic <0.001 0.986 –0.791/0.031 (0.124/0.001)
Potassium Whole blood refrigerated 3 12 Linear <0.001 0.978 2.999 (0.191)
Quadratic <0.001 0.999 4.758/–0.13 (0.156/0.001)
Potassium Serum/plasma RT 6 25 Linear <0.001 0.839 0.811 (0.108)
Quadratic <0.001 0.910 –0.295/0.028 (0.282/0.007)
Potassium Serum/plasma refrigerated 6 25 Linear 0.001 0.614 0.070 (0.018)
Quadratic 0.002 0.647 0.137/–0.001 (0.055/0.001)
ALT Whole blood RT 7 47 Linear 0.007 0.385 –0.066 (0.023)
Quadratic 0.018 0.404 –0.026/0.000 (0.05/0.0001)
ALT Whole blood refrigerated 3 15 Linear 0.182 0.352 –0.019 (0.013)
Quadratic 0.272 0.426 0.017/0.000 (0.040/0.0001)
ALT Serum/plasma RT 4 20 Linear 0.752 0.073 0.009 (0.029)
Quadratic 0.022 0.588 0.176/–0.001 (0.060/0.000)
ALT Serum/plasma refrigerated 3 16 Linear 0.238 0.302 0.020 (0.016)
Quadratic 0.160 0.480 0.087/0.000 (0.045/0.0001)
fPSA Whole blood RT 3 11 Linear 0.001 0.839 –0.370 (0.076)
Quadratic <0.001 0.967 –1.047/0.032 (0.126/0.006)
fPSA Whole blood refrigerated 1 4 Linear 0.007 0.966 –0.252 (0.039)
Quadratic 0.066 0.967 –0.245/0.000 (0.201/0.009)
fPSA Serum/plasma RT 3 11 Linear 0.002 0.806 –0.094 (0.022)
Quadratic 0.002 0.861 –0.196/0.001 (0.061/0.0001)
fPSA Serum/plasma refrigerated 3 10 Linear <0.001 0.977 –0.153 (0.011)
Quadratic <0.001 0.987 –0.239/0.001 (0.038/0.0001)
PSA Whole blood RT 3 9 Linear 1 0
Quadratic 0.99 0.025
PSA Whole blood refrigerated 0 0 – – –
PSA Serum/plasma RT 2 7 Linear <0.001 0.948 –0.041 (0.006)
Quadratic 0.001 0.964 –0.064/0.000 (0.017/0.0001)
PSA Serum/plasma refrigerated 2 6 Linear 0.061 0.732 –0.010 (0.004)
Quadratic 0.191 0.750 –0.020/0.000 (0.021/0.0001)
n, number of included studies; RT, room temperature. Slope: regression unstandardized coefficient for time (h) (linear model), time (h)/time 
(h)2 (quadratic model), time (h)/time (h)2/time (h)3 (cubic model). Bold: non significant.
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due to a different behavior in the first 24 h and in the later 
time points. There is an initial period of up to 12–18 h in 
which the phosphorus decreased (possibly explained by 
entry into the red blood cells), from 18 to 24 h phospho­
rus increased exponentially, rising to 400% in 2–3  days 
(probably by degradation of the phosphate esters) [2, 3] 
(Figure 3).
For potassium, a temperature­dependent behavior 
was observed, similar to glucose, but in the opposite direc­
tion. In refrigerated whole blood, it undergoes a greater 
increase of approximately 3%/h, which is clearly observed 
in the first hour of storage. Nevertheless, at room tem­
perature, no significant modification was seen in the first 
24 h. After 24 h, the function changes to a linear increase 
similar to that observed in the refrigerated samples. This 
behavior also seems to occur in serum/plasma at room 
temperature, however, a clear increase in the refrigerated 
sample was not observed, with a weaker adjustment of the 
 equation (r <0.7) (Figure 4).
For ALT, there are some studies indicating an 
increase and others indicating a decrease in both whole 
blood and serum/plasma. Only in the case of whole 
blood at room temperature a significant regression line 
may be estimated, with a weak fit (r = 0.3), in the rest 
of conditions it was not possible to adopt a consensus 
equation (Figure 5).
For free PSA, a very similar decrease in serum/
whole blood was observed in both refrigeration and 
room temperature. It could even be simplified in a 
single model with a decrease of 0.25%/h. This was sig­
nificant in all cases with an acceptable linear model. In 
the case of PSA, there were few studies, with no appar­
ent loss of stability over time. A significant adjustment 
was not achieved except in the serum/plasma sample at 
room temperature, where there was a slight decrease of 
0.04%/h (Figure 6).
Figure 1: Glucose stability in basic conditions.
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Figure 2: Glucose stability dependency on temperature.
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Figure 4: Potassium stability in basic conditions.
Figure 3: Phosphorus stability in basic conditions.
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These functions can be used to define stability limits 
applying several specifications for maximum allowable 
error. For glucose, when considering very demanding 
specifications (desirable sistematic error based on biologi­
cal variation 2.34% [52]) or mild specifications (minimum 
consensus specifications from Spain 12% [53]) the stability 
limit would range between 2 and 13 h in whole blood at RT 
and between 22 and 111 h in refrigerated serum (Table 3).
Discussion
In laboratory medicine, traceability of the pre­analytical 
phase is essential. Two critical aspects are the storage 
temperature and the time from sample collection until 
its processing. The loss of stability is likely to involve an 
unacceptable error in the result of a measured component 
that may lead to wrong clinical decisions. That is why 
laboratories should define stability limits for each analyte 
and sample, and use them as a cause of rejection before 
processing the sample, in spite of no apparent visible 
deterioration [54].
In this study we considered the possibility of using 
the cummulative information from multiple studies to 
generate a consensus function of stability in specific situ­
ations of stability for some magnitudes with known stabil­
ity problems. Four of the selected analytes to validate this 
method were well known to be stability­affected; glucose, 
potassium, phosphorus and PSA and one analyte with 
doubts about stability (ALT).
The first step was to grade the quality of the stabil­
ity studies. The quality of the published stability studies 
with the designed checklist is acceptable/excellent in the 
majority of cases (80%), although some usual defects 
were detected. A high percentage of studies did not con­
sider essential variables such as evaporation (52%), 
light exposure (73%), or agitation (69%). In the design 
of the checklist, it was originally thought to consider the 
absence of control of these variables as a reason for direct 
rejection of the study, as well as the absence of statisti­
cal study. We observed later that the main problem was 
the absence of primary data and this frequently concurred 
with low quality articles. In 11 of 48  studies (23%) no 
usable primary data were available, neither in table nor 
in figure form. This prevents the results from being con­
firmed by other studies. Rejected studies included the 
three ones classified as unacceptable.
A possible explanation to this variability is the 
absence of guidelines or recommendations regarding the 
Figure 5: ALT stability in basic conditions.
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way a stability study should be carried out. An  agreement 
on the metric to be used is the minimum deemed nec­
cesary. When dealing with a systematic error, it would 
be reasonable to use the percent deviation in relation to 
time, as recommended by the German Society of Clinical 
Chemistry [1] or by CLSI for reagent estability [55].
Figure 6: PSA stability in basic conditions.
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In our non­exhaustive literature review, data were col­
lected from about four to eight studies for each minimum 
study condition (specimen and temperature), with an 
average of 10–30 points for each model. With this number 
of studies we achieved reliable consensus functions in 
most of the magnitudes with a reasonable statistical con­
fidence in the model. In the magnitudes studied, it was 
possible to define a basic model (whole blood and serum 
at room temperature or refrigerated) that could cover 
general working conditions in four of them including PSA, 
in spite of the low number of studies included. For ALT it 
was not possible due to the heterogeneity of the results. 
This magnitude was selected because its instability was 
only occasionally mentioned. This approach seems inef­
fective in defining any small loss of stability that should 
be demonstrated by conclusive experimental studies.
In the case of phosphorus, if strict specifications are 
applied (desirable systematic error, 3.4%) stability is lost 
in the first 3 h due to the initial decrease. However, with 
more extensive specifications, (desirable total error 10%; 
minimum consesus specification 16%) there would be no 
loss of stability until 16–18 h, during the second phase of 
increase. In fact, some authors have reported 3 h stability 
for phosphate [13, 39], while others have described 24 and 
even 72 h [2, 3, 24, 26, 49].
In the case of potassium, contradictory results were 
obtained. In serum, the stability is lower at room tem­
perature than refrigerated, conversely as occurs in whole 
blood. The theoretical mechanism of onset of potassium is 
the output of intracellular content that should be depend­
ent on the number of residual cells (greater in plasma than 
in serum) and dependent on the same manner of inactiva­
tion of ATPase by cold [56]. It is very likely that the way of 
preparation and separation in the experiments is a very 
important factor to consider in their comparability.
For glucose, contact with cells and temperature were 
well known factors of instability. In whole blood a differ­
ence of 5–10 °C could double the loss of stability. However, 
the definition of maximum allowable error could be the 
main factor that justifies the differences in published 
 stability limits.
The stability limit for a magnitude depends on the 
storage conditions defined by the laboratory, but also 
largely on the specifications that are selected to define the 
maximum alowable error.
The usual definition of total analytical error (TAE) 
does not include components of systematic error due to 
the sample, which considers the effect of stability loss or 
deterioration by in vitro hemolysis, among others [57]. The 
design of all laboratory methods includes the selection of 
the most appropriate specimen/sample and the accept­
ability conditions of the sample, which usually appear 
as a rule of thumb; “stable in whole blood with EDTA for 
8 h...”, however, it is widely known that deterioration is 
usually a continuous function over time, depending on 
the physical­chemical conditions of the sample. For blood 
samples, time, temperature, contact with atmospheric air, 
or light exposure and agitation can substantially modify 
the deterioration function in a predictable amount if com­
plete traceability of preanalitical phase were avalaible. 
Consensus statement from the 1st Strategic Conference 
of the European Federation of Clinical Chemistry and 
Laboratory Medicine stated “it is acknowledged that, for 
patient care, optimizing the quality of the total (pre­ana­
lytical/analytical/post­analytical) examination process is 
the ultimate goal and therefore it would be desirable to go 
beyond setting analytical performance specifications and 
to establish examination performance. In principle, the 
performance specifications for the pre­ and post­analyti­
cal laboratory processes should follow the models as for 
analytical performance specifications. When components 
of these additional phases can be expressed in numerical 
terms, they should be added in defining examination per­
formance specifications” [58].
We found that in many cases the adjustment of the 
stability curves is not linear, even in the case of phospho­
rus a biphasic behavior was detected. It is important to 
note that in clinical samples there may be multiple simul­
taneous effects that could provoke unexpected responses 
in stability of clinical samples.
As limitations of this study it is necessary to empha­
size the non­exhaustive nature of the bibliographical 
Table 3: Stability limit for glucose applying different specifcations for maximum allowable error to the consensus stability model.
Specification Maximun allowable error, % Stability limit, h
Whole blood RT Serum/plasma refrigerated
Sistematic error (BV) 2.34 2 22
Total error (BV) 6.96 7 64
RCAP 8 8 74
Consensus minimum specifications 12 13 111
Brought to you by | Universitat de Lleida
Authenticated
Download Date | 12/19/18 10:43 AM
Gómez Rioja et al.: Laboratory sample stability.: is it possible to define a consensus stability function?      1817
search. The aim was to test a strategy of unification of 
results that has only been possible to verify in magnitudes 
with known problems of stability and for basic conditions. 
There are likely to be many more stability studies that 
could expand and improve the model. In the case of ALT, 
which we chose as an example of magnitude considered 
stable although a decrease in enzymatic activity would 
be expected over time, the results of the studies are very 
discordant despite being considered of adequate quality. 
For these cases, new studies would be necessary, which 
should be carried out ideally contemplating all the possi­
ble variables and a standardized design. The development 
of an international guide on stability testing would be very 
useful for the future comparability of these studies.
In conclusion, we propose a quality graduation and 
unification tool of stability studies on literature that could 
be useful to define a consensus stability function in spe­
cific conditions that could help laboratories to define sta­
bility limits using their own quality specifications.
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